We are live on ! Find out more
BG

Bahl & Gaynor Portfolio holdings

AUM $19.8B
1-Year Est. Return 19.53%
This Fund
S&P 500
This Quarter Est. Return
+9.04%
1 Year Est. Return
+19.53%
3 Year Est. Return
+63.97%
5 Year Est. Return
+84.2%
10 Year Est. Return
+296.44%
AUM
$19.4B
AUM Growth
+$1.52B
Cap. Flow
+$55.8M
Cap. Flow %
0.29%
Top 10 Hldgs %
32.2%
Holding
350
New
17
Increased
136
Reduced
148
Closed
7

Top Buys

Rank Stock Value
1
PPL
PPL Corp
PPL
+$52.8M
2
OKE icon
Oneok
OKE
+$39.9M
3
MDLZ icon
Mondelez International
MDLZ
+$34.3M
4
HPQ icon
HP
HPQ
+$32.7M
5
TRV icon
Travelers Companies
TRV
+$32.4M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$52.6M
2
UPS icon
United Parcel Service
UPS
+$52.2M
3
CVX icon
Chevron
CVX
+$43.4M
4
ABT icon
Abbott
ABT
+$41.4M
5
ETN icon
Eaton
ETN
+$36.2M

Sector Composition

Rank Sector Weight
1 Technology 22.95%
2 Financials 14.09%
3 Healthcare 13.94%
4 Industrials 11.47%
5 Consumer Staples 10.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FISV
126
Fiserv Inc
FISV
$27.9B
$12M 0.06%
67,051
-880
-1% -$145K
DOV icon
127
Dover
DOV
$28.4B
$12M 0.06%
62,665
-175
-0.3% -$31.9K
LMAT icon
128
LeMaitre Vascular
LMAT
$1.86B
$12M 0.06%
129,328
+856
+0.7% +$74.2K
ENSG icon
129
The Ensign Group
ENSG
$10.7B
$11.9M 0.06%
83,084
+627
+0.8% +$89.3K
GIL icon
130
Gildan
GIL
$10.6B
$11.9M 0.06%
+253,547
New +$10.7M
PAG icon
131
Penske Automotive Group
PAG
$14.2B
$11.9M 0.06%
73,023
+5,242
+8% +$836K
NSP icon
132
Insperity
NSP
$2.01B
$11.4M 0.06%
129,899
+5,000
+4% +$463K
NVS icon
133
Novartis
NVS
$297B
$11.3M 0.06%
98,572
-3,623
-4% -$411K
MKTX icon
134
MarketAxess Holdings
MKTX
$5.72B
$10.9M 0.06%
42,687
-1,551
-4% -$364K
CW icon
135
Curtiss-Wright
CW
$25.5B
$10.8M 0.06%
32,851
+206
+0.6% +$61K
CSGS
136
DELISTED
CSG Systems International
CSGS
$10.7M 0.05%
219,246
-87,784
-29% -$4M
CHE icon
137
Chemed
CHE
$7.22B
$10.6M 0.05%
17,694
+86
+0.5% +$48.8K
TTEK icon
138
Tetra Tech
TTEK
$9.07B
$10.3M 0.05%
218,300
+1,555
+0.7% +$69.2K
ROP icon
139
Roper Technologies
ROP
$39.8B
$10.2M 0.05%
18,335
-1,338
-7% -$736K
GOOG icon
140
Alphabet (Google) Class C
GOOG
$4.32T
$9.97M 0.05%
59,623
+769
+1% +$130K
RMD icon
141
ResMed
RMD
$30.7B
$9.81M 0.05%
40,173
-1,680
-4% -$375K
WMT icon
142
Walmart Inc
WMT
$890B
$9.66M 0.05%
119,577
-48
-0% -$3.52K
CCI icon
143
Crown Castle
CCI
$32.2B
$9.62M 0.05%
81,062
-1,508
-2% -$166K
FFBC icon
144
First Financial Bancorp
FFBC
$3.53B
$9.42M 0.05%
373,170
-69,823
-16% -$1.75M
USPH icon
145
US Physical Therapy
USPH
$1.22B
$9.35M 0.05%
110,503
+4,027
+4% +$357K
AJG icon
146
Arthur J. Gallagher & Co
AJG
$63.6B
$9.18M 0.05%
32,630
-601
-2% -$169K
GOOGL icon
147
Alphabet (Google) Class A
GOOGL
$4.33T
$8.97M 0.05%
54,073
+112
+0.2% +$18.8K
FSS icon
148
Federal Signal
FSS
$7.83B
$8.84M 0.05%
94,598
+546
+0.6% +$49.9K
V icon
149
Visa
V
$677B
$8.6M 0.04%
31,266
-1,673
-5% -$452K
SON icon
150
Sonoco
SON
$5.74B
$8.34M 0.04%
152,639
+11,150
+8% +$583K

Similar funds

Bahl & Gaynor's Q3 2024 Portfolio in Review

As of Q3 2024, Bahl & Gaynor held 350 positions worth $19.4B, up 8.5% from $17.9B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bahl & Gaynor's Q3 2024 filing shows 17 new, 136 increased, 148 reduced and 7 closed positions. Its largest new stake was Gildan: 253,547 shares worth $11.9M. The largest sale was Amgen, an estimated $52.6M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.

  • Bahl & Gaynor's largest Q3 2024 buy was Gildan: 253,547 shares worth $11.9M.
  • Bahl & Gaynor added most to PPL Corp in Q3 2024, an estimated $52.8M increase.
  • Bahl & Gaynor's biggest Q3 2024 reduction was Amgen, cutting an estimated $52.6M.
  • Bahl & Gaynor fully exited Stepan Co in Q3 2024, selling an estimated $1.63M.
  • Bahl & Gaynor's ten largest holdings make up 32% of its $19.4B portfolio in Q3 2024.
  • Bahl & Gaynor opened 17 new positions and closed 7 in Q3 2024.
  • Bahl & Gaynor's portfolio value rose 8.5% quarter-over-quarter to $19.4B.

Based on Bahl & Gaynor's 13F filing for Q3 2024, filed 12 Nov 2024.